Human exposure to radiation and the resulting acute radiation syndrome (ARS) have often been associated with accidents, but the contemporary world also faces growing concerns regarding terrorism that may involve the dispersal of enriched radioactive substances. These events may result in substantial casualties. Therefore, there is an urgent need for the development of countermeasures.

The current medical management of ARS remains far from satisfactory; the best available supportive care, including intravenous (IV) hydration, antiemetics, analgesics, antibiotics, and blood transfusions, can achieve an LD~50/60~ value only between 5.5 and 6.5 Gray (Gy) \[[@CR1]\]. The reported "successful" pharmacological interventions are radio-protectants, which are administered before radiation exposure, such as that encountered in the event of a nuclear attack; with the exception of the aforementioned supportive care approved by the U.S. Food and Drug Administration, no treatment is administered after radiation exposure, \[[@CR2]\]. Administration of bioactive substances, which are given IV in most cases, has also been tested, with limited success. Such substances include cytokines manufactured *in vitro* and designed to control hematopoiesis and local inflammatory responses that are pathogenic at high levels. At present, they are very costly and have been shown to be effective for a limited number of conditions \[[@CR3]\]. Thus, none of these proposed countermeasures are ready to be implemented during a mass-casualty scenario, nor does their use appear to be realistic. Nevertheless, these prospective treatments may be more effective in the presence of other types of treatment, such as responsive cell therapy.

Mesenchymal stem cells (MSCs) are beneficial for the treatment of medical conditions requiring tissue regeneration. Although the current clinical use of MSCs is limited to trials for diseases other than ARS, their unique biological features, such as migration, homing, multi-potency, and minimal host rejection, enable their wider application in medicine. Identification of their underlying mechanisms may greatly improve the prospects of using MSC-based therapies for unmet medical needs, including the treatment of ARS.

ARS represents a diverse and complicated pathology, which varies according to the radiation dose and the tissues exposed. Therefore, highly adaptable strategies are required for the treatment of ARS. In humans, a total body irradiation (TBI) dose of 1 Gy or more is considered to be sufficient to cause ARS \[[@CR4]\]. Various data support that the LD~50/60~ is between 3.5 and 5.5 Gy \[[@CR4]\]. Organ-specific sensitivity to radiation has been frequently discussed. Because of their greater numbers of rapidly proliferating cells, the hematopoietic system and gastrointestinal (GI) tract are considered to be the major target organs for the treatment of ARS. Specific pathologies of these organs are often referred to as hematopoietic syndrome and gastrointestinal (GI) syndrome, respectively. Although both organs contain a large repertoire of cells with different sensitivities to radiation, the consensus is that hematopoietic syndrome becomes evident at a TBI dose of 1 Gy or more, whereas GI syndrome becomes evident at a TBI dose of 5.5 Gy or more \[[@CR4]\].

Stem cell therapy has been introduced in the field of regenerative medicine as a highly adaptable transplantation method \[[@CR5]\]. The reported advantages of using stem cells include the ability to self-renew, with a differentiation potential determined by the surrounding microenvironment \[[@CR5]\]; the low probability of transplant rejection \[[@CR6]\]; the feasibility of IV infusion and rapid distribution to the sites of injury because of cell homing properties \[[@CR7]\]; and the possibility of *ex vivo* concentration, differentiation, and expansion \[[@CR8]\]. Stem cells have gained much attention because of their use in various clinical settings and animal disease models, including ARS, which has prompted continuous investigations aimed at their widespread application in regenerative medicine.

Different types of stem cells have been reported. These include neural stem cells \[[@CR9]\], hematopoietic stem cells (HSCs) \[[@CR10]\], and multi-potent mesenchymal stem cells (MSCs) with limited differentiation potential. They also exhibit different sensitivities to radiation. For instance, HSCs are extremely sensitive to radiation \[[@CR11]\], suggesting that their transplantation may be considered for the treatment of hematopoietic syndrome \[[@CR12]\]. Selecting the right types of stem cells at specific proportions appears to be important for their successful application \[[@CR13]\].

MSCs are mainly isolated from the bone marrow and are more resistant to radiation than HSCs \[[@CR11]\]. Following nearly two hundred phase II/III clinical trials, MSC therapy has emerged as one of the most advanced approaches in the treatment of many disorders; more than 1,400 patients enrolled in clinical trials have received the first marketed formulation of MSC Prochymal® (Osiris Therapeutics, Inc., 7015 Albert Einstein Drive, Columbia, MD 21046 USA), with no report of serious adverse events linked to treatment \[[@CR14]\]. It has been established that in many disease models, IV-infused MSCs closely mimic patient resident MSCs that, in response to chemotactic homing signals released from the sites of local injuries, leave the bone marrow, enter the circulation, and travel to sites of tissue damage \[[@CR15]\]. Importantly, these infused cells generally retain their properties and reduce inflammation \[[@CR16]\], modulate the allogeneic immune response \[[@CR17]\], and stimulate hematopoiesis \[[@CR13], [@CR18]\]. These are important additions to the already appreciated properties of MSCs, which replenish lost cell types, including those found in the nervous system, skin, bone, fat, cartilage, tendon, muscles (cardiac and skeletal), epithelia (lung, gut, and kidney), and other tissues. A recent study reported that in mice with acute radiation injury, MSCs infused *via* IV exerted protective and therapeutic effects through hematopoietic stimulation \[[@CR13]\]. Further mechanistic studies and advances are eagerly awaited.

This article of *Military Medical Research* features the report of Eaton and Varney \[[@CR19]\], who illustrate the possible use of MSC therapy for the treatment of ARS from the point of view of military medicine. The effect of MSC therapy on hematopoietic and GI syndrome, as well as cutaneous and combined-injury, is under debate as military personnel are likely to suffer wound trauma. In addition, a practical issue related to actual production timelines is the feasibility of using MSC therapy for military medical management in the event of a nuclear disaster, which is highly unpredictable.

The favorable effects of MSCs on the hematopoietic system have been demonstrated both *in vitro* and *in vivo*. MSCs have been shown to secrete an array of cytokines *in vitro*, which may support the growth of HSCs and their progeny in an *ex vivo* environment \[[@CR20]\]. An *in vitro* study found that MSCs support the growth of irradiated CD34^+^ cells \[[@CR21]\], which necessitates further investigation to determine an efficacious ratio of HSC-MSC co-transplantation for the treatment of radiation-induced hematopoietic syndrome \[[@CR22], [@CR23]\]. Irrespective of the medical disorders treated, patient demographics, and treatment regimen, clinical trials employing HSC grafts generally have revealed better HSC graft rates in the presence of MSCs \[[@CR24]--[@CR27]\]. This is particularly encouraging considering the anticipated limited availability of HSCs under mass-casualty scenarios and situations in which transplanted HSCs are likely to be obtained from two immunologically disparate donors \[[@CR28], [@CR29]\]. There has been successful clinical of HSC-MSC co-transplantation following radiation or chemotherapy administered for the treatment of both malignant and non-malignant disorders. Such data support the idea that MSC therapy is a safe and effective treatment modality for facilitating hematopoietic recovery and overall survival following medical interventions that involve HSC transplantation \[[@CR17]\].

Clinical trials on the use of MSCs for the treatment of GI diseases have been reported. GI syndrome after radiation exposure is associated with the loss of the rapidly dividing cells, including crypt and immune cells, which are important for epithelial integrity. This loss results in a breach of the epithelial barrier and immune dysregulation, increasing the probability of serious bacterial infection. MSCs have shown significant efficacy in improving certain types of inflammatory bowel diseases, including graft vs. host disease (GvHD) and Crohn's disease \[[@CR30], [@CR31]\]. There has also been a report of the systemic allogeneic infusion of MSCs in accidentally over-irradiated prostate cancer patients with radiation-induced colitis, in which patients experienced a reduction in pain, diarrhea, hemorrhage, inflammation, and fistulization \[[@CR32]\]. This evidence, together with the reports of enhanced crypt cell regeneration, restitution of the stem cell niche, and increased xylose absorption following MSC infusion in irradiated animals \[[@CR33]\], may be of value in establishing optimal MSC therapy regimens for the treatment of radiation-induced GI syndrome.

The benefits of using MSCs for skin-wound healing in the presence and absence of radiation have been discussed. Regardless of the presence of radiation injury, the administration of MSCs shortens the time for skin-wound healing \[[@CR34], [@CR35]\]. Other evidence, including the mobilization of MSCs from the bone marrow in response to wounding \[[@CR36]\], has revealed the key roles of MSCs in wound healing.

Collectively, the potential application of MSC therapy for ARS treatment has received much attention and warrants further investigation. Critical reviews, such as this editorial, discussing the outstanding issues regarding the feasibility and safety of MSC-based therapies contributes to the successful management of ARS in the military.

Conclusion {#Sec1}
==========

Treatment of ARS calls for innovative approaches. Although their application is not the front-runner in the treatment of ARS, MSC-based therapies are beneficial for the treatment of various clinical conditions because they directly complement the lost tissues while indirectly creating the microenvironment required for tissue regeneration. Further studies on the efficacy, molecular mechanisms, feasibility, and safety of MSC-based therapies in appropriate models are necessary for the successful management of ARS. Evaluation of the applications of MSCs in the treatment of a broad range of medical conditions, including ARS, will promote improvement in both military and civilian medicine.
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